Head And Neck Cancer
Study reveals ‘multifaceted consequences’ of cisplatin shortage
Findings presented at ASCO Quality Care Symposium provided new insights into the effects last year’s cisplatin shortage had on patients with head and neck cancer.
Mouthwash test could detect risk for recurrence of head and neck cancer
A mouthwash-based biomarker test has demonstrated efficacy for detecting risk of head and neck cancer recurrence, according to results of a nonrandomized clinical trial.
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.
Insurance status may affect access to high-quality, guideline-concordant cancer care
Insurance status contributes to considerable disparities in care quality for patients with head and neck cancer, according to retrospective study results.
Obesity associated with longer survival in immunotherapy-treated head, neck cancer
An analysis of patients with head and neck squamous cell carcinoma who received immune checkpoint inhibitors showed those with obesity survived longer than those with normal BMI.
‘Sobering’ data show excessive cannabis use increases risk for head and neck cancer
Individuals with cannabis-related disorder exhibited increased risk for head and neck cancer, results of a retrospective cohort study showed.
Quitting smoking after cancer diagnosis may alter prognosis, provide ‘dramatic’ benefits
Individuals with laryngeal cancer who stop smoking in the 2- to 4-week window between diagnosis and their first treatment can significantly improve their response to therapy, survival rates and quality of life.
Phase 3 trial of combination for advanced head, neck cancer halted due to lack of benefit
A randomized phase 3 trial designed to evaluate xevinapant with chemoradiotherapy as treatment for certain patients with head and neck cancers has been discontinued due to likely lack of benefit, according to the agent’s manufacturer.
Fluorescent dye to mark nerves may improve head, neck cancer surgery
A phase 3 clinical trial will evaluate a nerve fluorescing product designed to illuminate nerves during head and neck tumor removal, allowing surgeons to locate them more easily.
mRNA vaccine reprograms immune system to attack glioblastoma
An mRNA cancer vaccine developed at University of Florida may have the ability to reprogram the immune system against glioblastoma, findings of a first-in-human trial showed.